PharmaTimesNews & Politicsnews

Pulsesight reports positive phase 1 data for PST‑611 in dry AMD

Monday, May 11, 2026John PinchingView original

Early safety and efficacy signals support move into repeat‑dose phase 2a trial

Read the full article on the original site.